Trial results

$HROW — TRIESENCE

HARROW, INC. (HROW) TRIESENCE: trial results in ocular inflammation and pain following cataract surgery, 2027.

Research by Catalyst Intel

The catalyst

"•TRIESENCE: A multicenter Phase 3 study evaluating TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery continues to enroll, with initial data expected in early 2027."

— Harrow, 8-K filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

HROW-TRIESENCE-2026

Company

HARROW, INC.

Kind

Trial results

Indication

ocular inflammation and pain following cataract surgery

Window

2027-01-01 – 2027-04-30

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-05-30; subscribers get it on the day.